Literature DB >> 27242951

Office-based Management of Recurrent Respiratory Papilloma.

Kevin M Motz1, Alexander T Hillel1.   

Abstract

This review will highlight the indications and benefits of office-based therapy for recurrent respiratory papillomatosis (RRP) and discuss the utilization of photo-dynamic lasers and adjuvant medical therapy in office-based settings. Office-based management of RRP allows for more timely interventions, is preferred by the majority of patients, and negates the risk of general anesthesia. Current literature argues for the utilization of KTP laser over CO2 laser for office-based treatment of RRP. Medical therapies for RRP are limited, but agents such as bevacizumab are promising and have been shown to reduce disease burden. Medical therapies that can induce disease remission are still needed. Office-based procedures save time and healthcare expenses compared to like procedures in the operating room. However, the increased frequency for office-based procedures predicts similar overall healthcare costs for office-based and OR laser excision of RRP. Office-based management of RRP is a feasible and well-tolerated strategy in appropriately selected patients with adequate local anesthesia.

Entities:  

Keywords:  Bevacizumab; HPV; Human papillomavirus; KTP laser; Office-based laryngology procedures; Potassium titanyl phosphate laser; RRP; Recurrent respiratory papillomatosis

Year:  2016        PMID: 27242951      PMCID: PMC4882927          DOI: 10.1007/s40136-016-0118-0

Source DB:  PubMed          Journal:  Curr Otorhinolaryngol Rep


  48 in total

1.  The quality of life and health utility burden of recurrent respiratory papillomatosis in children.

Authors:  Neil K Chadha; Jennifer Allegro; Michelle Barton; Michael Hawkes; Hayley Harlock; Paolo Campisi
Journal:  Otolaryngol Head Neck Surg       Date:  2010-11       Impact factor: 3.497

2.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

Authors:  Luisa L Villa; Kevin A Ault; Anna R Giuliano; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Darron R Brown; Alex Ferenczy; Diane M Harper; Laura A Koutsky; Robert J Kurman; Matti Lehtinen; Christian Malm; Sven-Eric Olsson; Brigitte M Ronnett; Finn Egil Skjeldestad; Margareta Steinwall; Mark H Stoler; Cosette M Wheeler; Frank J Taddeo; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Rocio Marchese; Mark T Esser; Janine Bryan; Kathrin U Jansen; Heather L Sings; Gretchen M Tamms; Alfred J Saah; Eliav Barr
Journal:  Vaccine       Date:  2006-05-15       Impact factor: 3.641

3.  Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis.

Authors:  Michael J Silverberg; Poul Thorsen; Henning Lindeberg; Linda A Grant; Keerti V Shah
Journal:  Obstet Gynecol       Date:  2003-04       Impact factor: 7.661

4.  Use of cidofovir in HPV patients with recurrent respiratory papillomatosis.

Authors:  M Grasso; M Remacle; V Bachy; S Van Der Vorst; G Lawson
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-23       Impact factor: 2.503

5.  Recurrent respiratory papillomatosis in children: a retrospective study of management and complications.

Authors:  A H Morgan; R P Zitsch
Journal:  Ear Nose Throat J       Date:  1986-09       Impact factor: 1.697

6.  The cost of juvenile-onset recurrent respiratory papillomatosis.

Authors:  D Bishai; H Kashima; K Shah
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2000-08

7.  Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis.

Authors:  Reza Rahbar; Sara O Vargas; Judah Folkman; Trevor J McGill; Gerald B Healy; Xiaolian Tan; Lawrence F Brown
Journal:  Ann Otol Rhinol Laryngol       Date:  2005-04       Impact factor: 1.547

8.  Identical human papillomavirus (HPV) genomic variants persist in recurrent respiratory papillomatosis for up to 22 years.

Authors:  Boštjan J Kocjan; Nina Gale; Irena Hočevar Boltežar; Katja Seme; Kristina Fujs Komloš; Lea Hošnjak; Polona J Maver; Mateja M Jelen; Irena Zupanič Pajnič; Jože Balažic; Mario Poljak
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

9.  Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study.

Authors:  J Scott McMurray; Nadine Connor; Charles N Ford
Journal:  Ann Otol Rhinol Laryngol       Date:  2008-07       Impact factor: 1.547

10.  Pulsed dye laser treatment of recalcitrant verrucae: a preliminary report.

Authors:  O T Tan; R M Hurwitz; T J Stafford
Journal:  Lasers Surg Med       Date:  1993       Impact factor: 4.025

View more
  1 in total

1.  Reusable vs disposable nasopharyngolaryngoscopes: Cost analysis and resident survey.

Authors:  Ryan Walczak; Mark Arnold; Jeewanjot Grewal; Xiao Yuan; Amar Suryadevara; Haidy Marzouk
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-12-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.